Supriya Lifescience Limited (NSE:SUPRIYA) — Market Cap & Net Worth
Market Cap & Net Worth: Supriya Lifescience Limited (SUPRIYA)
Supriya Lifescience Limited (NSE:SUPRIYA) has a market capitalization of $754.63 Million (Rs69.78 Billion) as of August 3, 2026. Listed on the NSE stock exchange, this India-based company holds position #9999 globally and #505 in its home market, demonstrating a 4.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Supriya Lifescience Limited's stock price Rs867.00 by its total outstanding shares 80482800 (80.48 Million). See SUPRIYA capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Supriya Lifescience Limited Market Cap History: 2021 to 2026
Supriya Lifescience Limited's market capitalization history from 2021 to 2026. Data shows growth from $418.88 Million to $754.63 Million (19.08% CAGR).
Index Memberships
Supriya Lifescience Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$150.62 Billion | 0.50% | #68 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.26 Trillion | 0.02% | #407 of 750 |
Weight: Supriya Lifescience Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Supriya Lifescience Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Supriya Lifescience Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Supriya Lifescience Limited's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.35x
Supriya Lifescience Limited's market cap is 0.35 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $418.88 Million | $3.85 Billion | $1.24 Billion | 0.11x | 0.34x |
| 2022 | $203.90 Million | $5.19 Billion | $1.52 Billion | 0.04x | 0.13x |
| 2023 | $273.60 Million | $4.51 Billion | $898.57 Million | 0.06x | 0.30x |
| 2024 | $643.92 Million | $5.70 Billion | $1.19 Billion | 0.11x | 0.54x |
| 2025 | $654.10 Million | $6.96 Billion | $1.88 Billion | 0.09x | 0.35x |
Competitor Companies of SUPRIYA by Market Capitalization
Companies near Supriya Lifescience Limited in the global market cap rankings as of August 3, 2026.
Key companies related to Supriya Lifescience Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Supriya Lifescience Limited Historical Marketcap From 2021 to 2026
Between 2021 and today, Supriya Lifescience Limited's market cap moved from $418.88 Million to $ 754.63 Million, with a yearly change of 19.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs754.63 Million | +15.37% |
| 2025 | Rs654.10 Million | +1.58% |
| 2024 | Rs643.92 Million | +135.35% |
| 2023 | Rs273.60 Million | +34.18% |
| 2022 | Rs203.90 Million | -51.32% |
| 2021 | Rs418.88 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Supriya Lifescience Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $754.63 Million USD |
| MoneyControl | $754.63 Million USD |
| MarketWatch | $754.63 Million USD |
| marketcap.company | $754.63 Million USD |
| Reuters | $754.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more